Adina Ionac

Prof. Dr. Adina Ionac


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
R(Raluca Coifan (Șoșdean)
Raluca Coifan (Șoșdean)
MMMonica Mircea
Monica Mircea
PSPescariu Silvius-Alexandru
Pescariu Silvius-Alexandru
OVOana Voinescu
Oana Voinescu
BEBogdan Enache
Bogdan Enache
CMCristian Mornos
Cristian Mornos
Background/Objectives: Alcohol septal ablation (ASA) is an established interventional therapy for patients with obstructive hypertrophic cardiomyopathy (OHCM) who remain symptomatic despite optimal medical treatment. Nevertheless, 10–20% of patients fail to achieve a satisfactory hemodynamic or clinical response, highlighting the need for improved patient selection. Given that mitral valve (MV) morphology plays a central role in left ventricular outflow tract (LVOT) obstruction, we aimed to evaluate the impact of MV anatomical parameters on ASA outcomes. Methods: We retrospectively analyzed 38 OHCM patients who underwent ASA and had complete echocardiographic data before and at 6-month follow-up. Patients were stratified into responders (n = 32, defined as >50% reduction in LVOT pressure gradient and/or residual LVOT gradient < 50 mmHg) and non-responders (n = 6, <50% reduction or persistent gradient ≥ 50 mmHg), consistent with criteria used in previous ASA outcome studies. MV parameters—including redundant anterior mitral leaflet (AML) length, posterior mitral leaflet (PML) projection, and anterior displacement of the coaptation point (AML/PML projection ratio)—were compared between groups. Results: Non-responders demonstrated significantly greater AML redundancy (13.16 ± 1.72 vs. 9.96 ± 1.99 mm, p < 0.001), larger PML projection (18.5 ± 3.78 vs. 13.65 ± 3.8 mm, p = 0.006), and lower AML/PML projection ratio (0.80 ± 0.15 vs. 1.34 ± 0.45, p = 0.007). These parameters were associated with reduced post-procedural LVOT gradient reduction in univariate logistic regression (p = 0.01, p = 0.027, p = 0.015, respectively). Multivariate modeling was not pursued due to collinearity among MV parameters and the limited number of non-responder events, which precluded robust adjustment. Conclusions: Mitral valve morphological features—particularly redundant AML, greater PML projection, and anterior displacement of the coaptation point—were associated with suboptimal ASA outcomes in univariate analysis. These data emphasize the need for comprehensive MV imaging in pre-procedural assessment. Integrating MV morphology into current selection algorithms may refine ASA patient selection and improve long-term success rates.

6 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAlexandra Catalina Frisan
Alexandra Catalina Frisan
MLMihai-Andrei Lazăr
Mihai-Andrei Lazăr
R(Raluca Coifan (Șoșdean)
Raluca Coifan (Șoșdean)
SCSimina Crisan
Simina Crisan
DBDaniel Miron Brie
Daniel Miron Brie
CMCristian Mornos
Cristian Mornos
Left ventricular myocardial work (MW) has emerged as a valuable echocardiographic parameter for evaluating cardiac function and predicting clinical outcomes. Unlike conventional indices such as left ventricular ejection fraction and global longitudinal strain, MW integrates myocardial deformation with left ventricular pressure, providing a load-adjusted and physiologically meaningful assessment of myocardial performance. Growing evidence demonstrates that impaired MW is consistently associated with adverse outcomes, including heart failure hospitalization, mortality, and functional deterioration, across a wide spectrum of cardiovascular conditions such as ischemic heart disease, valvular heart disease, and cardiomyopathies. The noninvasive estimation of MW using commercially available echocardiographic software has enhanced its feasibility in routine clinical practice, enabling improved risk stratification and early identification of high-risk patients. This review summarizes current evidence supporting the prognostic value of MW, highlights its incremental role beyond conventional echocardiographic parameters, and discusses future perspectives for its integration into everyday clinical decision-making.

14 August 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
AMAdrian Grigore Merce
Adrian Grigore Merce
Daniel Dumitru NisulescuDaniel Dumitru Nisulescu
Daniel Dumitru Nisulescu
Anca HermeneanAnca Hermenean
Anca Hermenean
AMAdrian-Petru Merce
Adrian-Petru Merce
IMIulia Rauca Munteanu
Iulia Rauca Munteanu
CMCristian Mornos
Cristian Mornos
Background: Extensive prior work has established severe aortic stenosis as a whole-heart remodeling process involving chronic pressure overload, concentric hypertrophy, myocardial stiffness, and progressive ventricular fibrosis. However, direct paired histological characterization of both atria remains limited. Methods: This single-center observational comparative study included 28 patients with severe aortic stenosis referred for surgical aortic valve replacement and 14 coronary artery bypass grafting (CABG) controls without significant valvular disease, consecutively enrolled between 9 May 2024 and 28 April 2025. Left- and right-atrial tissue samples were collected intraoperatively. The relative expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta) was quantified by RT-qPCR using pooled tissue samples and interpreted descriptively as a group-level molecular output. Atrial fibrosis was measured histologically at the patient level using Masson’s trichrome staining and digital image analysis. Results: Compared with CABG controls, patients with severe aortic stenosis demonstrated greater left-atrial fibrosis (median: 19.12% [IQR: 16.12–23.12] vs. 11.54% [9.53–14.29]; p < 0.0001) and right-atrial fibrosis (16.33% [15.07–19.13] vs. 8.40% [5.75–11.27]; p = 0.0001). Pooled RT-qPCR outputs descriptively suggested higher IL-6, TNF-alpha, and TGF-beta expression in both atria, although biological replication was insufficient for inferential testing. Echocardiographically, the aortic stenosis group showed higher aortic jet velocity and transvalvular gradients, thicker ventricular walls, a larger right-ventricular diameter, higher pulmonary artery systolic pressure, and a larger estimated left-atrial volume. A sensitivity analysis of 13 within-group correlations found that no correlation retained statistical significance at q < 0.05. Exploratory regressions restricted to patient-level histological outcomes suggested that severe aortic stenosis status remained associated with left- and right-atrial fibrosis after limited adjustment for age and sex. Conclusions: These findings complement the extensive ventricular fibrosis literature by providing paired human biatrial tissue evidence of greater atrial fibrosis in severe aortic stenosis compared with CABG controls. The pooled molecular findings remain descriptive and require validation using patient-level biological measurements.

26 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAlina-Ramona Cozlac
Alina-Ramona Cozlac
CSCaius Glad Streian
Caius Glad Streian
MBMarciana Boca
Marciana Boca
SCSimina Crisan
Simina Crisan
MLMihai-Andrei Lazăr
Mihai-Andrei Lazăr
CLConstantin Tudor Luca
Constantin Tudor Luca
Background/Objectives: Thoracic aortic aneurysms (TAAs) are potentially life-threatening medical conditions, and their etiology involves both genetic and multiple risk factors. Coxiella burnetii endocarditis is one of the most frequent causes of blood culture-negative infective endocarditis (BCNIE) in patients with previous cardiac surgery. Our review aims to emphasize the importance of genetic testing in patients with thoracic aortic aneurysms but also the importance of additional testing in patients with suspected endocarditis whose blood cultures remain negative. The reported case has a history of acute DeBakey type I aortic dissection that developed during her second pregnancy, for which the Bentall procedure was performed at that time. Ten years after the surgery, the patient started developing prolonged febrile syndrome with repeatedly negative blood cultures, the serological tests revealing the presence of an infection with Coxiella burnetii. Considering her family history and the onset of her aortic pathology at a young age, genetic tests were performed, disclosing a missense variant in the actin alpha-2 (ACTA2) gene in heterozygous status. Methods: For a better understanding of both conditions, our research was conducted in two directions: one reviewing the literature on patients with Coxiella burnetii BCNIE and the other focusing on patients who had a familial thoracic aortic aneurysm (FTAA) due to the ACTA2 variant. This review incorporates studies found on PubMed and ResearchGate up to August 2024. Conclusions: BCNIE represents a condition with several diagnostic challenges and may lead to severe complications if timely treatment is not initiated. Also, diagnosing an FTAA requires genetic testing, enabling better follow-up and management.

29 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAlina-Ramona Cozlac
Alina-Ramona Cozlac
CSCaius Glad Streian
Caius Glad Streian
MBMarciana Boca
Marciana Boca
SCSimina Crisan
Simina Crisan
MLMihai-Andrei Lazăr
Mihai-Andrei Lazăr
CLConstantin Tudor Luca
Constantin Tudor Luca
Background/Objectives: Thoracic aortic aneurysms (TAA) represent medical conditions having causes that can range from genetic determinations to various risk factors, having potential life-threatening complications, the familial TAA (FTAA) being a cluster of non-syndromic thoracic aortic aneurysms. This review aims to emphasize the importance of genetic testing in patients diagnosed with thoracic aortic aneurysms, the genetic implications accounting for roughly 20% of these cases. The reported case presents a patient who was genetically tested 10 years after a Bentall procedure, which was performed for acute DeBakey type I aortic dissection developed in her second pregnancy, when the patient started presenting recurrent prolonged febrile syndrome. She was tested positive for a missense variant in the actin alpha-2 (ACTA2) gene, in heterozygous status, but also serological tests revealed the presence of an infection with Coxiella burnetii. Methods: For a better understanding of both conditions, our research was conducted on two directions, one reviewing the literature on patients with Coxiella burnetii blood culture-negative infective endocarditis (BCNIE) and the other one, focusing on patients having familial thoracic aortic aneurysm (FTAA) due to ACTA2 mutation. This review incorporates studies found on PubMed and ResearchGate up to August 2024. Conclusions: BCNIE represents a condition with several diagnosis challenges and may lead to severe complications if timely treatment is not initiated. Also, diagnosing FTAA requires more frequent genetic testing, enabling a better follow-up and management.

Verified
Journal Article
Open access
PDF file
Dana Emilia MovilaDana Emilia Movila
Dana Emilia Movila
AMAlexandru Catalin Motofelea
Alexandru Catalin Motofelea
Simona DrãganSimona Drãgan
Simona Drãgan
ASAdalbert Schiller
Adalbert Schiller
AIAdina Ionac
Adina Ionac
FCFlorina Caruntu
Florina Caruntu
Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer glucose-lowering, cardio-protective and reno-protective properties. Mortality rates constitute a central endpoint for understanding the overall clinical value of SGLT2 inhibitors. This systematic review and meta-analysis aims to compare mortality outcomes associated with SGLT2 inhibitors across different populations. A systematic search was performed in four databases—PubMed, Scopus, Web of Science (WOS) and Cochrane CENTRAL—in March 2025. We strictly included randomized controlled trials (RCTs) that compared patients who received SGLT2is to control patients regarding mortality outcomes. All-cause mortality up to one year, all-cause mortality more than one year, cardiovascular mortality, renal mortality and in-hospital mortality were the extracted outcomes. Finally, RevMan (5.4) was adopted for meta-analysis, and OpenMeta analyst software was adopted for meta-regression. Fifty clinical trials met the eligibility criteria of the current systematic review and meta-analysis. SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80–0.99], p = 0.03). This early survival benefit was primarily driven by the subgroup of patients treated during acute cardiac decompensation (RR = 0.76, 95% CI [0.60–0.97], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85–0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses). Cardiovascular mortality was also significantly reduced overall (RR = 0.88, 95% CI [0.84–0.94], p < 0.0001), with the greatest benefit observed in chronic heart failure and CKD subgroups. SGLT2 inhibitors as a class provide a consistent and significant reduction in all-cause mortality across both short-term (up to one year) and long-term follow-up. The early survival benefit is particularly evident when initiated during acute cardiac decompensation, while the long-term benefit extends to chronic heart failure, CKD, and high-risk DM. Future well-designed trials are needed to address the impact of less-explored SGLT2 inhibitors and understudied populations.